News

Featured

Almost one-third of UK rare rheumatic patients face a five-year wait for diagnosis

A new report by (RAIRDs) highlights the struggle to access diagnosis and care for rare autoimmune rheumatic disease patients.

Featured

SRUK’s response to the Government’s Spring Statement

The impact of the Government’s recent Spring Statement will be felt across our community. Many people living with Scleroderma and Raynaud's could face new hardship, as they are forced to rely on disability benefits and financial help just to get by.

Featured

Be Part Of The Answer

This Raynaud’s Awareness Month, we are calling on the public to #BePartOfTheAnswer and join the thousands of people already involved in what we hope will be the largest-ever study into Raynaud's. You can help us by sharing the online test with your own family and friends, and encourage them to find out if they could be living with Raynaud's.

Wednesday 30th March 2016

Halfway Point Marked in Scleroderma Patient Enrolment for Cytori's ECCS-50 Phase 3 Trial

Cytori Therapeutics has enrolled and treated its 40th patient with scleroderma in the Phase 3 STAR clinical trial for ECCS-50, marking 50 percent of target enrollment.

Read Article